Skip to main content
Premium Trial:

Request an Annual Quote

Scienion Adds Czech Firm BioVendor to Growing List of Immunoassay Manufacturing Clients


German array company Scienion recently announced that BioVendor, a provider of medical equipment and research products, is using Scienion's instruments to develop and manufacture in vitro diagnostic and research-use immunoassays, as well as antibodies and recombinant proteins.

CEO Holger Eickhoff told BioArray News this week that BioVendor, based in Brno, Czech Republic, is the latest Scienion customer to announce its adoption of the German firm's tools for manufacturing immunoassays. Other companies that have publicly discussed their relationship with Scienion include Toronto-based SQI Diagnostics, Maine Manufacturing, and Genalyte, he said.

According to Eickhoff, BioVendor is using a number of Scienion products in its manufacturing process, including its SciFlexarrayer dispensers, SciPlex microtiter plates, and SciReader CL for detection of assay results, according to Scienion.

He said that BioVendor's SciFlexarrayers are configured with the Berlin-based company's SciDrop Pico and Nano capabilities. Pico delivers between 50 and 800 picoliters per droplet, while Nano enables the delivery of between eight and 200 nanoliters per droplet, he said. Both offer Scienion customers "an increased range in liquid handling and feature sizes of spots and lines," Eickhoff noted.

BioVendor CEO Viktor Růžička said in a statement that the company is using Scienion's tools to develop new multiplex tests in microtiter plates. Among the IVDs in development is a test for Borrelia infections.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.